Aligos Therapeutics

Aligos Therapeutics is a clinical-stage pharmaceutical company currently dedicated to developing novel therapies to address unmet medical needs in viral and liver diseases. Aligos Therapeutics leverages its proprietary oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens aimed at enhancing therapeutic outcomes. Aligos Therapeutics’ primary focus is on developing a functional cure for chronic hepatitis B (“CHB”), which often leads to other life-threatening conditions such as cirrhosis, end-stage liver disease (“ESLD”), and the most common form of liver cancer, hepatocellular carcinoma (“HCC”). Aligos Therapeutics is discovering and developing novel compounds that can directly interact with disease-causing molecules. These approaches target viral nucleic acids and their encoded proteins, as well as oncogenes and their synthetic proteins. The company is also pursuing new therapeutic agents designed to activate the immune system to address diseases that cause significant morbidity and mortality.